The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Research Report 2025
Synopsis
Market Analysis and Insights: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is projected to reach US$ 12560 million by 2028, from US$ 11880 million in 2021, at a CAGR of 0.8% during 2022-2028.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Segment by Application
Hospitals
Clinics
Labs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
Market Analysis and Insights: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is projected to reach US$ 12560 million by 2028, from US$ 11880 million in 2021, at a CAGR of 0.8% during 2022-2028.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Segment by Application
Hospitals
Clinics
Labs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.4 Entry and Fusion Inhibitors
1.2.5 Protease Inhibitors (PIs)
1.2.6 Integrase Inhibitors
1.2.7 Coreceptor Antagonists
1.3 Market by Application
1.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Perspective (2017-2028)
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Region
2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Dynamics
2.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Trends
2.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
2.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Challenges
2.3.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue
3.1.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
3.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio
3.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2021
3.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Area Served
3.6 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
3.7 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Type
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2023-2028)
5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Application
5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2017-2028)
6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022)
6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2017-2028)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2017-2028)
9.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie, Inc.(U.S.)
11.1.1 AbbVie, Inc.(U.S.) Company Detail
11.1.2 AbbVie, Inc.(U.S.) Business Overview
11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.1.5 AbbVie, Inc.(U.S.) Recent Development
11.2 Merck & Co., Inc. (U.S.)
11.2.1 Merck & Co., Inc. (U.S.) Company Detail
11.2.2 Merck & Co., Inc. (U.S.) Business Overview
11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.2.5 Merck & Co., Inc. (U.S.) Recent Development
11.3 Bristol-Myers Squibb Company (U.S.)
11.3.1 Bristol-Myers Squibb Company (U.S.) Company Detail
11.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development
11.4 Boehringer Ingelheim GmbH (Germany)
11.4.1 Boehringer Ingelheim GmbH (Germany) Company Detail
11.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development
11.5 Genentech, Inc. (U.S.)
11.5.1 Genentech, Inc. (U.S.) Company Detail
11.5.2 Genentech, Inc. (U.S.) Business Overview
11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.5.4 Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.5.5 Genentech, Inc. (U.S.) Recent Development
11.6 Cipla, Inc. (India)
11.6.1 Cipla, Inc. (India) Company Detail
11.6.2 Cipla, Inc. (India) Business Overview
11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
11.6.5 Cipla, Inc. (India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Key Players of Entry and Fusion Inhibitors
Table 5. Key Players of Protease Inhibitors (PIs)
Table 6. Key Players of Integrase Inhibitors
Table 7. Key Players of Coreceptor Antagonists
Table 8. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Region (2017-2022)
Table 12. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Region (2023-2028)
Table 14. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends
Table 15. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
Table 16. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Challenges
Table 17. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
Table 18. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players (2017-2022)
Table 20. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2021)
Table 21. Ranking of Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
Table 25. Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2017-2022)
Table 29. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2023-2028)
Table 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2017-2022)
Table 33. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2023-2028)
Table 35. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 38. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 39. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 40. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 41. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 42. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 43. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 44. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 45. AbbVie, Inc.(U.S.) Company Detail
Table 46. AbbVie, Inc.(U.S.) Business Overview
Table 47. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 48. AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 49. AbbVie, Inc.(U.S.) Recent Development
Table 50. Merck & Co., Inc. (U.S.) Company Detail
Table 51. Merck & Co., Inc. (U.S.) Business Overview
Table 52. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 53. Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Merck & Co., Inc. (U.S.) Recent Development
Table 55. Bristol-Myers Squibb Company (U.S.) Company Detail
Table 56. Bristol-Myers Squibb Company (U.S.) Business Overview
Table 57. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 58. Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Bristol-Myers Squibb Company (U.S.) Recent Development
Table 60. Boehringer Ingelheim GmbH (Germany) Company Detail
Table 61. Boehringer Ingelheim GmbH (Germany) Business Overview
Table 62. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 63. Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Boehringer Ingelheim GmbH (Germany) Recent Development
Table 65. Genentech, Inc. (U.S.) Company Detail
Table 66. Genentech, Inc. (U.S.) Business Overview
Table 67. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 68. Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Genentech, Inc. (U.S.) Recent Development
Table 70. Cipla, Inc. (India) Company Detail
Table 71. Cipla, Inc. (India) Business Overview
Table 72. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 73. Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Cipla, Inc. (India) Recent Development
Table 75. Research Programs/Design for This Report
Table 76. Key Data Information from Secondary Sources
Table 77. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Features
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 4. Entry and Fusion Inhibitors Features
Figure 5. Protease Inhibitors (PIs) Features
Figure 6. Integrase Inhibitors Features
Figure 7. Coreceptor Antagonists Features
Figure 8. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application in 2021 & 2028
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Labs Case Studies
Figure 12. Human Immunodeficiency Virus (HIV)-1 Therapeutics Report Years Considered
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Region: 2021 VS 2028
Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players in 2021
Figure 17. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2021
Figure 19. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2017-2028)
Figure 21. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2017-2028)
Figure 25. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Region (2017-2028)
Figure 33. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2017-2028)
Figure 41. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2017-2028)
Figure 45. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. AbbVie, Inc.(U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 48. Merck & Co., Inc. (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 49. Bristol-Myers Squibb Company (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 50. Boehringer Ingelheim GmbH (Germany) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 51. Genentech, Inc. (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 52. Cipla, Inc. (India) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2017-2022)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
